Literature DB >> 11923348

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

D J Diekema1, S A Messer, A B Brueggemann, S L Coffman, G V Doern, L A Herwaldt, M A Pfaller.   

Abstract

Bloodstream infections due to Candida species cause significant morbidity and mortality. Surveillance for candidemia is necessary to detect trends in species distribution and antifungal resistance. We performed prospective surveillance for candidemia at 16 hospitals in the State of Iowa from 1 July 1998 through 30 June 2001. Using U.S. Census Bureau and Iowa Hospital Association data to estimate a population denominator, we calculated the annual incidence of candidemia in Iowa to be 6.0 per 100,000 of population. Candida albicans was the most common species detected, but 43% of candidemias were due to species other than C. albicans. Overall, only 3% of Candida species were resistant to fluconazole. However, Candida glabrata was the most commonly isolated species other than C. albicans and demonstrated some resistance to azoles (fluconazole MIC at which 90% of the isolates tested are inhibited, 32 microg/ml; 10% resistant, 10% susceptible dose dependent). C. glabrata was more commonly isolated from older patients (P = 0.02) and caused over 25% of candidemias among persons 65 years of age or older. The investigational triazoles posaconazole, ravuconazole, and voriconazole had excellent in vitro activity overall against Candida species. C. albicans is the most important cause of candidemia and remains highly susceptible to available antifungal agents. However, C. glabrata has emerged as an important and potentially antifungal resistant cause of candidemia, particularly among the elderly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923348      PMCID: PMC140380          DOI: 10.1128/JCM.40.4.1298-1302.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.

Authors:  D J Diekema; M A Pfaller; S A Messer; A Houston; R J Hollis; G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.

Authors:  H M Blumberg; W R Jarvis; J M Soucie; J E Edwards; J E Patterson; M A Pfaller; M S Rangel-Frausto; M G Rinaldi; L Saiman; R T Wiblin; R P Wenzel
Journal:  Clin Infect Dis       Date:  2001-06-20       Impact factor: 9.079

4.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

5.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group.

Authors:  L Saiman; E Ludington; M Pfaller; S Rangel-Frausto; R T Wiblin; J Dawson; H M Blumberg; J E Patterson; M Rinaldi; J E Edwards; R P Wenzel; W Jarvis
Journal:  Pediatr Infect Dis J       Date:  2000-04       Impact factor: 2.129

7.  The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

Authors:  A S Kao; M E Brandt; W R Pruitt; L A Conn; B A Perkins; D S Stephens; W S Baughman; A L Reingold; G A Rothrock; M A Pfaller; R W Pinner; R A Hajjeh
Journal:  Clin Infect Dis       Date:  1999-11       Impact factor: 9.079

8.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

9.  Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.

Authors:  Y F Berrouane; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 10.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

View more
  118 in total

1.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Drug resistance is not directly affected by mating type locus zygosity in Candida albicans.

Authors:  Claude Pujol; Shawn A Messer; Michael Pfaller; David R Soll
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

4.  Use of a panfungal PCR assay for detection of fungal pathogens in a commercial blood culture system.

Authors:  Peter C Iwen; Alison G Freifeld; Tricia A Bruening; Steven H Hinrichs
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

5.  Accuracy and appropriateness of antimicrobial susceptibility test reporting for bacteria isolated from blood cultures.

Authors:  Daniel J Diekema; Kathleen Lee; Patti Raney; Loreen A Herwaldt; Gary V Doern; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

Review 6.  Prophylaxis and treatment of invasive candidiasis in the intensive care setting.

Authors:  L Ostrosky-Zeichner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

7.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

8.  NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.

Authors:  Clint S Schmidt; C Jo White; Ashraf S Ibrahim; Scott G Filler; Yue Fu; Michael R Yeaman; John E Edwards; John P Hennessey
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

9.  Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Authors:  Beth A Arthington-Skaggs; Wendy Lee-Yang; Meral A Ciblak; Joao P Frade; Mary E Brandt; Rana A Hajjeh; Lee H Harrison; Andre N Sofair; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  CHROMagar Candida as the sole primary medium for isolation of yeasts and as a source medium for the rapid-assimilation-of-trehalose test.

Authors:  Melissa P Murray; Riva Zinchuk; Davise H Larone
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.